After a record FY25, the drugmaker sees new growth engines in biologics, vaccines, and devices powering expansion in FY26.

Zydus Lifesciences is on analysts' radar. The stock rose nearly 2% on Wednesday after reporting mixed fourth-quarter results.

The company's net profit was at Rs 1,182 crore, with revenue at Rs 5,633 crore and EBITDA margin rising to 26.7 percent, in ...

ICICI Securities recommended hold rating on Zydus Lifesciences with a target price of Rs 910 in its research report dated May ...

Zydus Lifesciences Q4 stuns with margin guidance, but brokerages trim targets — stock ends at Rs 890. Should you follow ...

The Subject Expert Committee (SEC) on Haematology has recommended for grant of permission to conduct a Phase-III clinical ...

Zydus Lifesciences consolidated net profit slipped about 1 per cent year-on-year (Y-o-Y) to ₹1,171 crore in the March quarter ...

Zydus Lifesciences Ltd. reported growth in the fourth quarter of fiscal 2025, driven by higher non-recurring components in ...

The pharma companys Board has recommended a final dividend of Rs 11 per equity share of face value Rs 1 each, representing a ...

Morgan Stanley believes India's fundamentals remain strong, supported by macro stability, improving terms of trade, declining ...

Results: Zydus Lifesciences Q4FY25 net profit dips 1% to Rs 1,244 crore due to exceptional charge; revenue grows 17% to Rs ...

Indian drugmaker Zydus Lifesciences reported a higher adjusted fourth-quarter profit on Tuesday, driven by new drug launches in the U.S., its biggest market.